BiotechTube

mRNA-1273

PreclinicalCompleted
1 views this week 0 watching
0
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

SARS-CoV-2

Conditions

SARS-CoV-2

Trial Timeline

Sep 10, 2021 → Feb 4, 2022

NCT ID
NCT05366322

About mRNA-1273

mRNA-1273 is a preclinical stage product being developed by Moderna for SARS-CoV-2. The current trial status is completed. This product is registered under clinical trial identifier NCT05366322. Target conditions include SARS-CoV-2.

What happened to similar drugs?

4 of 20 similar drugs in SARS-CoV-2 were approved

Approved (4) Terminated (1) Active (16)
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1083ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1273.211ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
✅mRNA-1273 Variant-containing FormulationModernaApproved

Clinical Trials (14)

NCT IDPhaseStatus
NCT07266558ApprovedRecruiting
NCT06113692PreclinicalCompleted
NCT05894499PreclinicalCompleted
NCT05894590PreclinicalCompleted
NCT05894525PreclinicalCompleted
NCT05397223Phase 1Completed
NCT05366322PreclinicalCompleted
NCT04958304PreclinicalTerminated
NCT04958954PreclinicalCompleted
NCT04860297Phase 3Completed
NCT04796896Phase 3Completed
NCT04649151Phase 3Completed
NCT04470427Phase 3Completed
NCT04405076Phase 2Completed

Competing Products

20 competing products in SARS-CoV-2

See all competitors
ProductCompanyStageHype Score
mRNA-1010ModernaPhase 1
0
mRNA-1273ModernaPhase 1
0
mRNA-1283ModernaPhase 1
0
mRNA-1273ModernaPreclinical
0
mRNA-1083 Composition 1 Dose A Lot AModernaPhase 2
0
mRNA-1273.214ModernaPhase 2
0
SPIKEVAXModernaPreclinical
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1083.1ModernaPhase 2
0
SPIKEVAX BivalentModernaPreclinical
0
mRNA-1083ModernaPhase 3
0
mRNA-1273ModernaPhase 2
0
mRNA-1073ModernaPhase 2
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1273.211ModernaPhase 3
0
SPIKEVAX (mRNA-1273)ModernaPreclinical
0
mRNA-1083ModernaPhase 2
0